Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

386
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
386
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

368
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
368
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

208
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
208
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

335
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
335
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

388
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing integrated continuous bioprocesses in real time: Deviations in product quality.

Biotechnology progress·2023
Same author

Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study.

Biologicals : journal of the International Association of Biological Standardization·2019
Same author

Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and Insulins.

Therapeutic innovation & regulatory science·2018
Same author

Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs.

Journal of pharmaceutical sciences·2018
Same author

Hemodialysis patients' preferences for the management of anemia.

BMC nephrology·2017
Same author

Clinical factors influencing the decision to order red blood cell transfusions for a sample of US dialysis patients
.

Clinical nephrology·2017

Related Experiment Video

Updated: Mar 28, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

808

Study design is important for ESA biosimilars.

Allan Pollock, Gustavo Grampp

    Nephrology News & Issues
    |December 19, 2015
    PubMed
    Summary

    Biosimilars must be highly similar to reference drugs. For erythropoiesis-stimulating agents (ESAs), clinical trials are essential to confirm safety and efficacy due to likely structural differences.

    Area of Science:

    • Biopharmaceutical science
    • Regulatory science
    • Clinical pharmacology

    Background:

    • U.S. regulations mandate high similarity between biosimilars and reference products.
    • Biosimilars must demonstrate no clinically meaningful differences in safety, purity, or potency.
    • Analytical studies alone may not predict the clinical impact of structural differences in complex biologics.

    Purpose of the Study:

    • To address the challenges in biosimilar evaluation for erythropoiesis-stimulating agents (ESAs).
    • To highlight the limitations of analytical studies for predicting clinical outcomes of ESA biosimilars.
    • To recommend specific clinical trial endpoints for ESA biosimilars.

    Main Methods:

    • Review of U.S. regulatory requirements for biosimilars.

    More Related Videos

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    18.3K
    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.2K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
    08:58

    Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

    Published on: October 17, 2025

    808
    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    18.3K
    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.2K
  • Analysis of the complexities associated with evaluating ESA biosimilars.
  • Identification of critical clinical trial endpoints.

    • Main Results:

    • Structural differences in ESAs may not be fully predictable by analytical methods.
    • Clinical trials are necessary to bridge the gap between analytical data and clinical comparability.
    • Hemoglobin, dose, and immunogenicity are key endpoints for ESA biosimilar trials.

    Conclusions:

    • Evaluating ESA biosimilars requires a comprehensive approach beyond analytical characterization.
    • Clinical trials are crucial for demonstrating the safety and efficacy of ESA biosimilars.
    • Specific endpoints like hemoglobin, dose, and immunogenicity are vital for regulatory approval.